Who will get the first psychedelic approved? Compass Pathways and a nonprofit organization race toward regulatory approval

Compass Pathways is presented as one of the leading contenders in the race to secure approval for the first psychedelic drug. The description indicates that a nonprofit organization is also nearing its own efforts, suggesting a competitive development landscape rather than a single clear frontrunner. The supplied material does not identify the nonprofit, provide clinical or regulatory data, or explain which psychedelic compounds are involved. It therefore supports a high-level account of competition in psychedelic drug development, while leaving the candidates' evidence, timelines, safety profiles, and approval prospects unspecified.